Stockscreener 앱 받기
15.25
0.53%
0.08
시장 영업 전:
15.35
0.10
+0.66%
전일 마감가:
$15.17
열려 있는:
$15.21
하루 거래량:
1.21M
Relative Volume:
0.38
시가총액:
$1.28B
수익:
-
순이익/손실:
$-15.28M
주가수익비율:
-30.13
EPS:
-0.5061
순현금흐름:
$-32.97M
1주 성능:
+6.27%
1개월 성능:
-0.46%
6개월 성능:
+116.62%
1년 성능:
+403.30%
1일 변동 폭
$15.00
$16.09
1주일 범위
$14.73
$16.09
52주 변동 폭
$3.02
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.25 | 1.27B | 0 | -15.28M | -32.97M | -0.5061 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Price Action: Is Corvus Pharmaceuticals Inc undervalued by DCF analysis2026 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
Aug Drivers: What are the risks of holding Corvus Pharmaceuticals Inc2026 Setups & High Accuracy Swing Trade Signals - baoquankhu1.vn
Investment Review: Is Corvus Pharmaceuticals Inc a stock for growth or value investors - baoquankhu1.vn
Growth Recap: Will Corvus Pharmaceuticals Inc outperform during market rallies2026 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Corvus Pharmaceuticals: Strong Clinical Narrative, Already Priced For Success - Seeking Alpha
What analysts say about Corvus Pharmaceuticals Inc stockBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Fed Watch: Will Corvus Pharmaceuticals Inc benefit from green energy policies2026 Big Picture & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below Fifty Day Moving AverageWhat's Next? - marketbeat.com
Market Review: How cyclical is Corvus Pharmaceuticals Incs revenue streamWeekly Profit Analysis & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Corvus Pharmaceuticals, Inc. (CRVS) Options Chain - Yahoo! Finance Canada
CRVS Should I Buy - Intellectia AI
Vanguard amends ownership for Corvus Pharmaceuticals (NASDAQ: CRVS) after realignment - Stock Titan
Corvus leads drug developers as index climbs in early 2026 - BioWorld MedTech
Earnings Beat: Is Corvus Pharmaceuticals Inc undervalued by DCF analysisTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Movement Recap: What analysts say about Corvus Pharmaceuticals Inc stock - baoquankhu1.vn
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 8.4% HigherTime to Buy? - MarketBeat
Corvus Ignites: A 9.73% Surge Shakes the Market, But What Fuels the Flame? - Bitget
Income Plays: Can Corvus Pharmaceuticals Inc beat the S P 5002026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Is Corvus Pharmaceuticals Inc forming a breakout pattern2026 Growth vs Value & Accurate Buy Signal Notifications - baoquankhu1.vn
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - MSN
Is Corvus Pharmaceuticals’ Expanded US$200 Million ATM Facility Reframing Its Funding Story for CRVS? - Sahm
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Growth Recap: Will Corvus Pharmaceuticals Inc outperform tech stocksEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
A Look At Corvus Pharmaceuticals (CRVS) Valuation After Recent Share Price Swings - Sahm
FY2030 Earnings Forecast for CRVS Issued By HC Wainwright - MarketBeat
Corvus outlines cash runway into Q2 2028 and targets mid-2027 Phase II readout for soquelitinib in atopic dermatitis - MSN
Corvus Trials Progress And Cash Raise Reframe Soquelitinib Risk Reward Profile - Sahm
Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million - The Globe and Mail
Oppenheimer Remains a Buy on Corvus Pharmaceuticals (CRVS) - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Corvus Pharmaceuticals Bets Big on Soquelitinib Pipeline - TipRanks
CRVS Stock Receives Analyst Rating and Price Target Boost from O - GuruFocus
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Yahoo Finance
Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 6.5% After Earnings Miss - MarketBeat
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Corvus Pharmaceuticals, Inc. has signed a revised equity distribution agreement. - Bitget
Corvus Pharmaceuticals Expands ATM Equity Program to $200 Million With Jefferies - TradingView
Corvus Pharmaceuticals (NASDAQ: CRVS) launches $200M at-the-market stock program - Stock Titan
Corvus Pharmaceuticals (NASDAQ: CRVS) doubles Jefferies ATM capacity to $200M - Stock Titan
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals (CRVS) files S-3 shelf to offer stock, debt, warrants - Stock Titan
Oppenheimer raises Corvus Pharmaceuticals stock price target to $33 By Investing.com - Investing.com Canada
Corvus: Q4 Earnings Snapshot - theheraldreview.com
Corvus Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Decoding Corvus Pharmaceuticals Inc (CRVS): A Strategic SWOT Ins - GuruFocus
Corvus: Fourth Quarter Earnings Overview - Bitget
Corvus Pharmaceuticals rises on atopic dermatitis trial data By Investing.com - Investing.com South Africa
Earnings call transcript: Corvus Pharmaceuticals Q4 2025 Misses EPS Forecast - Investing.com
CRVS: Strong clinical and financial momentum with soquelitinib, supporting pipeline expansion and durability - TradingView
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
자본화:
|
볼륨(24시간):